Vaccines and antibiotic resistance
- PMID: 22981392
- DOI: 10.1016/j.mib.2012.08.002
Vaccines and antibiotic resistance
Abstract
Vaccines and antibiotics have significantly contributed to improve health and also to increase the longevity of human beings. The fast-acting effect of antibiotics makes them indispensable to treat infected patients. Likewise, when the causative agent of the infection is unknown and in cases of superinfections with different species of bacteria, antibiotics appear to be the only therapeutic option. On the contrary, vaccines are usually not efficacious in people already infected and their action is generally limited to a much narrowed range of pathogens. However, vaccines have contributed to the eradication of some of the most deadly infectious agents worldwide, can generate immunity to infections lasting for several years or life-long, and are able to induce herd immunity. Nonetheless, infectious diseases are still among the leading causes of morbidity and mortality worldwide. This is mainly owing to the emergence of bacterial resistance to antibiotics and the lack of efficacious medications to treat several other infectious diseases. Development of new vaccines appears to be a promising solution to these issues. Indeed, with the advent of new discovery approaches and adjuvants, today is possible to make vaccines virtually against every pathogen. In addition, while vaccine-resistant bacteria have never been reported, accumulating literature is providing evidence that vaccination can reduce the raise of antibiotic resistant strains by decreasing their use.
Copyright © 2012. Published by Elsevier Ltd.
Similar articles
-
Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents.Expert Rev Anti Infect Ther. 2011 Nov;9(11):1035-52. doi: 10.1586/eri.11.121. Expert Rev Anti Infect Ther. 2011. PMID: 22029522 Review.
-
New issues in infectious diarrhea.Rev Gastroenterol Disord. 2005;5 Suppl 3:S16-25. Rev Gastroenterol Disord. 2005. PMID: 17713455 Review.
-
Selection of antibiotic-resistant pathogens in the community.Pediatr Infect Dis J. 2006 Oct;25(10):974-6. doi: 10.1097/01.inf.0000239270.33190.71. Pediatr Infect Dis J. 2006. PMID: 17006309 Review.
-
What's new on the antimicrobial horizon?Int J Antimicrob Agents. 2008 Dec;32 Suppl 4:S207-13. doi: 10.1016/S0924-8579(09)70004-4. Int J Antimicrob Agents. 2008. PMID: 19134521 Review.
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
Cited by
-
Synthetic Immunobiotics: A Future Success Story in Small Molecule-Based Immunotherapy?ACS Infect Dis. 2018 May 11;4(5):664-672. doi: 10.1021/acsinfecdis.7b00261. Epub 2018 Feb 16. ACS Infect Dis. 2018. PMID: 29431421 Free PMC article.
-
Bacterial Outer Membrane Vesicles as a Versatile Tool in Vaccine Research and the Fight against Antimicrobial Resistance.mBio. 2021 Aug 31;12(4):e0170721. doi: 10.1128/mBio.01707-21. Epub 2021 Aug 10. mBio. 2021. PMID: 34372691 Free PMC article. Review.
-
Monosaccharide-Based Synthetic TLR4 Agonist Enhances Vaccine Efficacy against Pseudomonas aeruginosa Challenge.ACS Infect Dis. 2025 Apr 11;11(4):894-904. doi: 10.1021/acsinfecdis.4c00932. Epub 2025 Mar 24. ACS Infect Dis. 2025. PMID: 40129118 Free PMC article.
-
Development of a multi-epitope vaccine against Acinetobacter baumannii: A comprehensive approach to combating antimicrobial resistance.PLoS One. 2025 Mar 10;20(3):e0319191. doi: 10.1371/journal.pone.0319191. eCollection 2025. PLoS One. 2025. PMID: 40063635 Free PMC article.
-
Vaccine Evolution and Its Application to Fight Modern Threats.Front Immunol. 2019 Jul 25;10:1722. doi: 10.3389/fimmu.2019.01722. eCollection 2019. Front Immunol. 2019. PMID: 31404139 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical